| Literature DB >> 23638021 |
Marie Paschaki1, Carole Schneider, Muriel Rhinn, Christelle Thibault-Carpentier, Doulaye Dembélé, Karen Niederreither, Pascal Dollé.
Abstract
Retinoic acid (RA), an active derivative of the liposoluble vitamin A (retinol), acts as an important signaling molecule during embryonic development, regulating phenomenons as diverse as anterior-posterior axial patterning, forebrain and optic vesicle development, specification of hindbrain rhombomeres, pharyngeal arches and second heart field, somitogenesis, and differentiation of spinal cord neurons. This small molecule directly triggers gene activation by binding to nuclear receptors (RARs), switching them from potential repressors to transcriptional activators. The repertoire of RA-regulated genes in embryonic tissues is poorly characterized. We performed a comparative analysis of the transcriptomes of murine wild-type and Retinaldehyde Dehydrogenase 2 null-mutant (Raldh2 (-/-)) embryos - unable to synthesize RA from maternally-derived retinol - using Affymetrix DNA microarrays. Transcriptomic changes were analyzed in two embryonic regions: anterior tissues including forebrain and optic vesicle, and posterior (trunk) tissues, at early stages preceding the appearance of overt phenotypic abnormalities. Several genes expected to be downregulated under RA deficiency appeared in the transcriptome data (e.g. Emx2, Foxg1 anteriorly, Cdx1, Hoxa1, Rarb posteriorly), whereas reverse-transcriptase-PCR and in situ hybridization performed for additional selected genes validated the changes identified through microarray analysis. Altogether, the affected genes belonged to numerous molecular pathways and cellular/organismal functions, demonstrating the pleiotropic nature of RA-dependent events. In both tissue samples, genes upregulated were more numerous than those downregulated, probably due to feedback regulatory loops. Bioinformatic analyses highlighted groups (clusters) of genes displaying similar behaviors in mutant tissues, and biological functions most significantly affected (e.g. mTOR, VEGF, ILK signaling in forebrain tissues; pyrimidine and purine metabolism, calcium signaling, one carbon metabolism in posterior tissues). Overall, these data give an overview of the gene expression changes resulting from embryonic RA deficiency, and provide new candidate genes and pathways that may help understanding retinoid-dependent molecular events.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23638021 PMCID: PMC3634737 DOI: 10.1371/journal.pone.0062274
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Description of the samples analyzed and summary of the microarray results.
(A–D) Profile views of mouse embryos (wild-type: A, C; Raldh2 −/− mutants: B, D) at the stages chosen for analysis. The embryos are not from the experimental series, but were collected from litters harboring a retinoic acid-sensitive (RARE-hsp68-lacZ) reporter transgene and processed for X-gal analysis, thereby illustrating the absence of detectable RA activity in the mutants. The collected samples were the anterior head region of 14 somite stage embryos (X-gal-labelled in control embryos, section planes illustrated by arrows: A, B) and the posterior region (X-gal-labelled in control embryos, section plane illustrated by arrows: C, D) of 4 somite stage embryos. (E, F) Principal component analysis illustration of ANT and POST data sets. Wild-type samples are depicted by blue dots, and Raldh2 −/− samples by red dots. For anterior tissues, wild-type and Raldh2 −/− samples segregate in two distinct groups. In the case of posterior tissues, one Raldh2 −/− sample (#046) did not cluster with the others, and was excluded from subsequent analyses. (G) VENN diagrams summarizing the numbers of genes showing statistically significant different expression levels, with a fold change of ±1.2 (upper numbers) or ±1.5 (lower, bold numbers). The numbers of genes exhibiting a “contradictory” behavior (upregulated in one type of samples, and downregulated in the other, as pointed out by the arrows) are also given.
Most severely downregulated genes in Raldh2 −/− tissue samples.
| DOWN in ANTERIOR TISSUES | ||
| Symbol | Name | Function |
|
| Inhibitor of DNA binding 4 | Regulation of transcription and cell proliferation, brain, hippocampus development |
|
| Signal transducer and activator of transcription 4 | Regulation of transcription and cell proliferation, signal transduction |
|
| Taf9b, TBP-associated factor | Regulation of transcription |
|
| Major facilitator superfamily domain containing 7B | Unknown |
|
| Carbonic anhydrase 3 | Lyase activity |
|
| Eph receptor A3 | Transmembrane receptor, protein kinase |
|
| Rhesus blood group-associated A glycoprotein | Ammonium transmembrane transporter |
|
| Synaptotagmin XI | Calcium transmembrane transporter |
|
| Protein tyrosine phosphatase, receptor type Z, polypeptide 1 | Axonogenesis |
|
| Carboxypeptidase A2 | Metallocarboxypeptidase |
|
| Neuropilin (NRP) and tolloid (TLL)-like 2 | Membrane receptor |
|
| Predicted gene 9983 | Unknown |
|
| Major facilitator superfamily domain containing 7B | Head, digits, and spleen development |
|
| Fatty acid binding protein 7, brain | Lipid transport, forebrain neurogenesis |
|
| Schlafen 9 | Unknown |
|
| Janus kinase and microtubule interacting protein 2 | Kinase, microtubule interacting protein |
|
| Solute carrier family 4 (anion exchanger), member 1 | Anion exchanger transport |
|
| Nuclear receptor 2E1 (Tlx) | Regulation of transcription, brain and eye development |
|
| Isopentenyl-diphosphate delta isomerase | Steroid and carotenoid biosynthesis |
|
| LON peptidase N-terminal domain and ring finger 2 | Unknown |
Genes listed by decreasing fold change in expression, ranging from −3.3 to −1.9.
Genes listed by decreasing fold change in expression, ranging from −4.5 to −1.7.
Genes listed alphabetically, fold change in expression <−1.5 in both the ANT and POST microarrays.
The table distinguishes the “top” downregulated genes in anterior or posterior tissues, and the genes affected in both types of samples.
Figure 2Volcano plots representing corrected p-values (ordinates, −log10 scale) from Student t-test of the mRNA levels compared in wild-type and Raldh2 −/− samples anterior (A) and posterior (B) embryonic tissue samples.
Genes with a fold change (abscissae) higher than 1.5 and a false discovery rate lower than 0.1 are shown in red.
Figure 3Details of the gene expression profiles obtained after hierarchical clustering of the experimental samples by relative gene expression level analysis.
Eight clusters (panels B–I) have been extracted from the overall clustering analysis (available as additional online information, Figure S1), showing differential gene expression behaviors according to the experimental samples (ANT, RNA from anterior tissues; POST, RNA from posterior tissues; WT, wild-type embryos; KO, Raldh2 −/− embryos). Gene expression profiles are illustrated as a heat map (green: weak expression; red: strong expression – see scale below). The expression profile of the Rarb gene is also shown (panel J), which did not cluster with any other gene. This analysis further validated the experimental samples, as WT and KO samples segregated into fully distinct clusters, both for the ANT and POST tissue samples (panel A above).
Figure 4Microarray validation by quantitative real-time RT-PCR (Q-PCR).
Genes were selected according to their different expression profiles as detected by microarray analysis of wild-type (WT) and Raldh2 −/− embryos. Among these, one gene (Pax6) was chosen as a “control”, as its expression had already been shown to be affected in Raldh2 −/− embryos (see main text for details and interpretation of the data). Expression levels are expressed as values normalized with respect to Gapdh (a housekeeping gene) mRNA levels (WT samples, blue bars; Raldh2 −/− samples, red bars). Data (mean ± SEM) were analyzed with Student t-test; ***, p<0.001; **, p<0.01; *, p<0.05.
Figure 5Validation of gene expression changes in Raldh2 −/− embryos by in situ hybridization (ISH).
A subset of the genes analyzed by Q-PCR yielded detectable signals when performing ISH with antisense riboprobes. Although less sensitive than Q-PCR, this technique allows to analyze mRNA tissue distributions. See main text for an interpretation of the data. Embryos are shown at the 4–6 somite stage for Pax6 (A: upper panels, ventral views; lower panels, dorsal views), Lhx2 (B: central panels) and Six2 (C: upper panels, profile views; lower panels, dorsal views), E9.5 for Lhx2 (B: upper panels, profile views; lower panels, forebrain frontal views), 6–7 somite stage (upper panels) and early limb bud (lower panels) stages for Crabp2 (D), 6 somite stage (upper views) and E9.5 (lower views) for Bhlhe40 (E). WT: wild-type embryos; −/−: Raldh2 −/− embryos.
Figure 6Overview of the main biological and physiological functions correlating with the affected genes in
The functions are listed by decreasing order of statistical significance [−log(p-values)] of differentially expressed and misregulated genes as calculated by the Ingenuity software. Left side (black bars): ANT microarray data; right side (gray bars): POST microarray data.
Figure 7Main classes of molecules downregulated in Raldh2 −/− embryonic tissues, according to Ingenuity pathway analysis of the transcriptomic data.
Pie charts illustrate the distribution of gene products according to subcellular location (A) or protein function (B), when considering the overall set of affected genes (fold change ±1.2, filtered for FDR <10% and a p-value ≤0.03 for POST and ≤0.05 for ANT).
Figure 8Summary diagram of the major molecular pathways emerging from Ingenuity analysis of the Raldh2 −/− transcriptome.
The molecular pathways are listed by decreasing order of statistical significance as they appear through analysis of the ANTERIOR (left-side list) and POSTERIOR (right-side list) data sets. The most significant pathways identified for each data set are highlighted in gray. Additional pathways relevant for developmental processes are also listed. A graphic representation of the numbers of genes downregulated (green) or upregulated (red) in anterior (upper bars) or posterior (lower bars) Raldh2 −/− embryonic tissue samples (fold change ±1.2, filtered for FDR <10%) is shown. The total number of genes comprising each pathway (middle line, gray shaded), and the percentages of genes misregulated in each experiment, are also given.
Genes acting in selected signaling pathways and misregulated in Raldh2 −/− tissue samples (ANT: anterior samples; POST: posterior samples).
| PATHWAY | ANT | ANT | POST | POST | |
| Upregulated | Downregulated | Upregulated | Downregulated | ||
|
| Ligands |
| Fgf13, Fgf17 | Fgf10, | |
| Receptors |
|
| |||
| Effectors | Akt3, Gab1, Map2k1, Map2k6, Map3k1, Mapk3, Mapk13, | Hras, Mapk11, Pik3c2B, Pik3cb, | Akt3, Frs2, Map3k1, | Mapk13, Hras | |
|
| Ligands |
| Bmp2, Bmp4, Bmp5 | ||
| Receptors | Bmpr1b | Bmpr2 | Bmpr1b | ||
| Effectors/Modulators |
| Ecsit, Hras, Mapk10, Mapk11, Mras, Prkag1, Prkag2, Prkar1b | Mapk10, Msx2, | Hras, Mapk13 | |
|
| Ligands | Inha, | Inha, | ||
| Receptors | Acvr2a, Ptgfr, Tgfbr2, Tgfbr3 | Tgfbr2, | |||
| Effectors/Modulators |
|
| Eng, Ltbp1, | Foxh1, Hras, Tgfbrap1 | |
|
| Ligands |
| |||
| Receptors | Ptch1 | Ptch2 | |||
| Effectors | Dyrk1b, Prkar1b, | Prkag2 | Prkar1b, Dyrk1b | Gli1 | |
|
| Ligands | Ctgf, Cyr61 | |||
| Receptors | Igf1r | Igf1r | |||
| Effectors/Modulators | Akt3, Igfbp2, | Hras, Pik3c2B, Pik3cb, | Akt3, | Hras | |
|
| Ligands | Figf, Pgf, | Pgf, | ||
| Receptors | Flt1, Flt4 | Flt1 | |||
| Effectors/Modulators |
| Eifay, Eif2b1, Eif2b4, Hif1a, Hras, Mras, Pik3c2B, Pik3cb, | Acta1, Actn2, Akt3, | Eif2b1, Eif2b4, Eif2s2, Hras | |
|
| Ligands |
|
|
|
|
| Receptors | Acvr2a, Cd44, | Fzd9, | Cd44, | Fzd4, | |
| Effectors/Modulators |
| Apc2, | Akt3, | Hnf1a, | |
|
| Synthesis enzymes |
| Rdh10 |
| |
| Metabolism enzymes | Cyp26c1 |
| |||
| Receptors | Rara, Rarg | Rarg |
| ||
| Effectors/Modulators | Cited2, Ncoa1, Nr2f1 (Coup-Tf1), Nr2f2 (Coup-Tf2), Pnrc1, | Crabp2, Gdap1, Gdap2 | Ncoa1, Pnrc1, Rarres2, |
|
Key: Bold indicates a fold change exceeding ±1.5.
Italics indicate a p-value >0.05 (ANT) or >0.03 (POST).
Figure 9VENN diagrams summarizing a cross-comparison of the genes downregulated in Raldh2 −/− embryos (A, anterior tissues; B, posterior tissues) with those identified as RAR-bound by ChIP-seq analysis of embryonic stem (ES) cells differentiating as embryoid bodies (ref.
[ ), and those induced after RA treatment of embryoid bodies. This analysis distinguished early RA-responsive genes (2 h after RA exposure: upper numbers; ref. [72]), from those identified at a later stage of differentiation (4 days post-RA treatment: lower numbers; ref. [73]). Some selected genes are highlighted in the intersecting data sets.
Bioinformatic analysis of putative transcription factor binding sites (oPOSSUM3 single site analysis method) in genes showing the highest downregulation in posterior or anterior tissues of Raldh2 −/− embryos.
| Transcription factor | Family | Gene hits | TFBS hits | Z-score | Transcription factor | Family | Gene hits | TFBS hits | Z-score |
|
| Nuclear receptor | 8 | 11 | 11.40 |
| Homeodomain | 107 | 679 | 21.90 |
|
| ββα zinc finger | 43 | 272 | 10.27 |
| Homeodomain | 124 | 1566 | 19.22 |
|
| Homeodomain | 48 | 262 | 9.90 |
| Homeodomain | 120 | 1115 | 17.73 |
|
| Forkhead | 40 | 222 | 8.14 |
| Homeodomain | 123 | 1574 | 15.15 |
|
| Forkhead | 40 | 152 | 7.84 |
| ββα zinc finger | 6 | 6 | 14.66 |
|
| Paired domain | 8 | 8 | 7.78 |
| Homeodomain | 109 | 938 | 13.98 |
|
| HMG group | 48 | 328 | 6.87 |
| HMG group | 88 | 379 | 12.99 |
|
| Homeodomain | 52 | 606 | 6.86 |
| HMG group | 112 | 782 | 10.28 |
|
| Homeodomain | 17 | 27 | 6.58 |
| HMG group | 109 | 558 | 10.16 |
|
| Arid | 48 | 494 | 6.08 |
| NFY CCAAT binding | 51 | 91 | 10.02 |
| NR2F1 | Nuclear receptor | 17 | 23 | 5.74 | Sox5 | HMG group | 99 | 554 | 8.86 |
| STAT1 | Stat | 19 | 40 | 5.49 | Foxd1 | Forkhead | 93 | 496 | 7.78 |
| HNF1A | Homeodomain | 14 | 16 | 5.36 | NKx3-1 | Homeodomain | 103 | 530 | 6.63 |
| Pdx1 | Homeodomain | 49 | 418 | 5.35 | Foxd3 | Forkhead | 85 | 340 | 5.86 |
| PBX1 | Homeodomain | 15 | 25 | 5.21 | Pou5f1 (Oct4) | Homeodomain | 26 | 40 | 5.81 |
| PPARG:RXRA | Nuclear receptor | 22 | 40 | 3.96 | Lhx3 | Homeodomain | 41 | 88 | 5.56 |
| Hoxa5 | Homeodomain | 52 | 607 | 3.70 | Foxo3 | Forkhead | 95 | 537 | 5.47 |
| T (Brachyury) | β-ribbon | 8 | 10 | 3.63 | NR3C1 (GR) | Nuclear receptor | 21 | 28 | 5.12 |
| STAT3 | Stat | 32 | 82 | 3.48 | HNF1B | Homeodomain | 33 | 54 | 4.70 |
| Pax6 | Paired domain | 5 | 6 | 3.26 | Foxa2 | Forkhead | 82 | 323 | 3.97 |
59 genes analyzed from 63 genes downregulated with FC <−1.5.
137 genes analyzed from 146 genes downregulated with FC <−1.5.
The searched region encompassed 5 Kb upstream and 5 Kb downstream of the transcription start site. The top ten factors (highest Z-scores) appear in bold. Additional transcription factors (below) are the authors' seelection.
Genes with conserved RAR:RXR (DR5) binding sites are: Csn3, Dhrs3, Fap, Meox1, Metrn, Rarb, Stra6, 5730596B20Rik (NB: 5730596B20Rik is an antisense EST found between the Hoxa3 and Hoxa4 genes).
Genes with conserved Pax5 binding sites are: Apba2, Crabp2, Lgr5, Mettl1, NKx2-9, Pmm2, Ripply3, Rfx6.
Genes with conserved NR2F1 binding sites are: Apba2, Crabp2, Dhrs3, Dusp9, Fap, Gcsh, Hoxa1, Maob, NKx2-9, Pax6, Prdm13, Rarb, Sfrp5, Stra6, Timm8a1, Tmem56, 1700011H14Rik.
Genes with conserved STAT1 binding sites are: Apba2, Dbx1, Dhrs3, Fap, Hoxa1, Gcsh, Kynu, Lgr5, Meox1, Pax6, Prdm13, Ptprz1, Rarb, Ripply3, Slc25a10, Snora34, Stra6, Timm8a1, 5730596B20Rik.
Genes with conserved PBX1 binding sites are: Ccne1, Dbx1, Fap, Hoxa1, Kynu, Lgr5, Nepn, Nkx2-9, Nkx3-1, Pax6, Prdm13, Rarb, Rfx6, Ripply3, Tmem56.
Genes with conserved PPARG:RXRA binding sites are: Apba2, Cpn1, Crabp2, Dbx1, Dhrs3, Dusp9, Gcsh, Hoxa1, Lhx1, Meox1, Mtap7d2, Nkx3-1, Pax6, Prdm13, Ptprz1, Rarb, Sh3bgrl2, Snord118, Stra6, Trmt61a, 1700011H14Rik, 5730596B20Rik.
Genes with conserved T binding sites are: Lhx1, NKx2-9, Pmm2, Prdm13, Stra6, Timm8a1, Trmt61a, 5730596B20Rik.
Genes with conserved Pax6 binding sites are: Dbx1, Pax6, Rarb, Stra6, 5730596B20Rik.
Genes with conserved REST binding sites are: Acsl6, Ank1, Cntnap2, Lhx2, Mpped1.
Genes with conserved Pou5fI binding sites are: Abcb10, Acsl6, Ank1, Apba2, Arrdc4, Aven, Cdh20, Cntnap2, Dhrs11, Gas5, Htr3b, Ikzf1, Lhx2, Mrpl18, Muc1, Neto2, Nova1, Nr2e1, Pak3, Pcdh19, Prdm16, Rragb, Shox2, Slc25a21, Taf1d, Wnt7a.
Genes with conserved NR3C1 binding sites are: Cntnap2, Eef1d, Fez1, Hsd17b7, Htr3b, Itgb8, Klf1, Lrcc4, Lhx2, Mpped1, Mrpl20, Nova1, Nsdhl, Pcdh19, Pdss1, Phyhipl, Pou3f3, Rnf144b, Shox2, Syt11, AI504432.
Transcription factor binding site (TFBS) analysis: genes downregulated in POSTERIOR tissues.
TFBS analysis: genes downregulated in ANTERIOR tissues.